Quanterix Corporation (QTRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
QTRX Chart
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input.
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.
Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Sung Ji Nam - Scotiabank Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today.
Quanterix Corporation Dividends
Quanterix Corporation Earnings
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
Quanterix Corporation (QTRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Quanterix Corporation ever had a stock split?
Quanterix Corporation Profile
| Medical - Devices Industry | Healthcare Sector | Dr. Masoud Toloue Ph.D. CEO | NASDAQ (NMS) Exchange | 74766Q101 Cusip |
| US Country | 471 Employees | - Last Dividend | - Last Split | 7 Dec 2017 IPO Date |
Overview
Quanterix Corporation, situated in Billerica, Massachusetts, represents a significant force in the life sciences sector, focusing on the development and marketing of cutting-edge digital immunoassay platforms that propel precision health forward. Initially known as Digital Genomics, Inc., the company underwent a rebranding to Quanterix Corporation in August 2007, marking a new chapter in its mission to revolutionize life sciences research and diagnostics. Its operations span globally, reaching North America, Europe, the Middle East, Africa, and the Asia Pacific regions. Quanterix has carved a niche in fields like neurology, oncology, cardiology, infectious diseases, and inflammation, establishing its prominence by serving a diverse client base that includes academic and governmental research institutions, pharmaceutical, biotechnology, and contract research companies. Through direct sales, support organizations, and a network of distributors or sales agents, Quanterix ensures its innovative products and services are accessible to those dedicated to advancing healthcare and medical research.
Products and Services
HD-X Instrument: This flagship product from Quanterix stands out as a powerful protein detection platform. The HD-X Instrument is designed for researchers who require highly sensitive, accurate, and scalable solutions for protein quantification, making it a cornerstone in the advancement of precision health.
SR-X Instrument: The SR-X Instrument broadens the application landscape for Simoa detection technology, offering researchers an adaptable tool for their experimental designs. Its ability to facilitate a wide range of applications makes it a versatile addition to the scientific toolkit, especially for those pushing the boundaries of detection and quantification in complex biological samples.
SP-X Instrument: Focused on Simoa planar array technology, the SP-X Instrument is specialized in the measurement of multiplex chemiluminescent immunoassays. It represents Quanterix's commitment to providing high-throughput, sensitive solutions for researchers working with multiplex assays, enhancing efficiency and data quality in laboratories worldwide.
Assays and Components: Quanterix offers a comprehensive range of assays and components, including all elements required to run enzyme-based immunoassays such as beads, capture and detector reagents, enzyme reagents, and substrates. This extensive product line supports the scientific community by simplifying the procurement process and ensuring that high-quality components are readily available for a multitude of research purposes.
Contract Research Services: Beyond its product offerings, Quanterix extends its expertise through a variety of contract research services. These services encompass sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services, reflecting Quanterix's dedication to supporting research projects with tailored, comprehensive solutions. By leveraging its state-of-the-art technology and scientific acumen, Quanterix serves as a valuable partner for organizations seeking to accelerate their research and diagnostic capabilities.
Contact Information
